Physician profile
Luz Anaya
NPI 1366209785
$855.64
in general payments reported to CMS, 2019-2025
15 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $367 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $247.82 | 2024-2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $122.83 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $119.45 | 2024 | Airsupra |
| Corcept Therapeutics | $57.84 | 2025 | Korlym |
| Amgen INC. | $54.08 | 2025 | Repatha, Otezla |
| Novo Nordisk INC | $48.98 | 2025 | Ozempic |
| Xeris Pharmaceuticals, INC. | $33.39 | 2025 | Recorlev |
| Vifor Pharma, INC. | $32.18 | 2025 | Veltassa |
| Abbott Laboratories | $26.47 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $24.58 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.00 | 2025 | Xifaxan |
| Azurity Pharmaceuticals, INC. | $18.60 | 2025 | Edarbyclor |
| Abbvie INC. | $17.71 | 2025 | |
| Mannkind Corporation | $17.15 | 2025 | |
| Glaxosmithkline, LLC. | $15.56 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luz Anaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.